A Study of LY3532226 in Participants With Obesity
Completed · Phase 1 · NCT06557356
Conditions: Obesity
At a glance
- Research payments reported, 2025
- $2.2M
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 132
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3532226 (drug), Placebo (drug)
- Dates
- Started 2024-08-16; completion 2025-12-12
- Results posted
- Not yet
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period.
From ClinicalTrials.gov, last updated 2026-01-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.2M in research payments for this study in 2025 (9 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hugh A. Coleman, DO Family Medicine · Daytona Beach, FL
- Kathleen M. Doisy, MD Pediatrics · Columbia, MO
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $1.5M
- Covance Clinical Research LP Dallas $349,072
- Fortrea Clinical Research Unit Inc $340,004
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.